Tectonic Therapeutic, Inc.
TX2100
Hereditary Hemorrhagic Telangiectasia (HHT)
Countdown
178days
Catalyst readout · ~ Jan 1, 2027 estimated
What's at stake
A key catalyst for TX2100 (Hereditary Hemorrhagic Telangiectasia (HHT)) is expected ~ Jan 1, 2027.
Primary source
· SEC 8-K
verified 14h ago
“Subject to favorable safety, tolerability and pharmacokinetic results, the Company plans to advance TX2100 into a Phase 2 proof-of-concept trial in patients with moderate-to-severe HHT in early 2027,”